The $1.7M is 100% (not 50%) of the US Tyzeka sales in the third quarter. The worldwide Tyzeka/Sebivo sales for the full year could still come close to $20M, however.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”